ALNY Stock Crash: The REAL Reason Alnylam Dropped 25% (Deep Investor Analysis)

AI-generated source summary

The video discusses the stock ALNY, which experienced a 25% plunge to a 52-week low of $174 on October 29, 2026, following Q3 earnings. Despite a reported 52% increase in total revenue, full-year guidance was lowered to the low end of estimates. The analysis highlights a dichotomy in Wall Street sentiment: Stifel downgraded ALNY to 'Hold' with a target of $225, citing the lack of near-term momentum. Conversely, H.C. Wainwright maintained a 'Buy' rating with a significantly higher target of $455, viewing the current situation as a potential 'confidence reset' rather than a fundamental collapse. The company's drug, AMVUTTRA, holds a 24% share of total TRx category prescriptions, with 33% of physicians having prescribed it, indicating strong long-term potential despite slow initial adoption. Challenges include a restrictive UnitedHealth policy on AMVUTTRA for Medicare Advantage effective October 1, 2026, and the 340B rule impacting hospital-based drug pricing. Management has postponed 2027 guidance until February 2027, awaiting clarity on the 340B rules, suggesting a focus on long-term credibility over short-term guesswork. The stock's current price of $174 is seen as a potential buying opportunity by some analysts, while others are more cautious due to regulatory headwinds and slow patient uptake.

AI-generated summary based on the source content.